BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 18070145)

  • 1. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
    Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation.
    Xu T; Ye F; Wang B; Tian C; Wang S; Shu K; Guo D; Lei T
    Neuro Endocrinol Lett; 2010; 31(1):147-54. PubMed ID: 20150876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors.
    Shi Y; Tang D; Deng J; Su C
    Chin Med J (Engl); 1998 Oct; 111(10):891-4. PubMed ID: 11189233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of activating mutations of CXCR4 in pituitary tumours.
    Lee YH; Noh TW; Lee MK; Jameson JL; Lee EJ
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):209-13. PubMed ID: 19473177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
    Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.
    Jaffrain-Rea ML; Rotondi S; Turchi A; Occhi G; Barlier A; Peverelli E; Rostomyan L; Defilles C; Angelini M; Oliva MA; Ceccato F; Maiorani O; Daly AF; Esposito V; Buttarelli F; Figarella-Branger D; Giangaspero F; Spada A; Scaroni C; Alesse E; Beckers A
    Endocr Relat Cancer; 2013 Oct; 20(5):753-66. PubMed ID: 23940012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas.
    Iwata T; Yamada S; Mizusawa N; Golam HM; Sano T; Yoshimoto K
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):499-502. PubMed ID: 17371465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
    Sakai N; Kim K; Sanno N; Yoshida D; Teramoto A; Shibasaki T
    Neurol Med Chir (Tokyo); 2008; 48(11):481-7; discussion 487-8. PubMed ID: 19029774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ghrelin mRNA and GH secretagogue receptor mRNA in human GH-producing pituitary adenomas is affected by mutations in the alpha subunit of G protein.
    Kim K; Sanno N; Arai K; Takano K; Yasufuku-Takano J; Teramoto A; Shibasaki T
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):630-6. PubMed ID: 14616888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
    Ezzat S; Zheng L; Winer D; Asa SL
    Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
    Georgitsi M; De Menis E; Cannavò S; Mäkinen MJ; Tuppurainen K; Pauletto P; Curtò L; Weil RJ; Paschke R; Zielinski G; Wasik A; Lubinski J; Vahteristo P; Karhu A; Aaltonen LA
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):621-7. PubMed ID: 18410548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited.
    Yasufuku-Takano J; Takano K; Morita K; Takakura K; Teramoto A; Fujita T
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):91-6. PubMed ID: 16402935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas.
    Kim HJ; Kim MS; Park YJ; Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Jung HW; Han DH; Lee HS; Chi JG
    J Endocrinol; 2001 Feb; 168(2):221-6. PubMed ID: 11182759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and pathogenesis of pituitary adenomas.
    Faglia G
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():1-5. PubMed ID: 8396832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
    Persani L; Borgato S; Lania A; Filopanti M; Mantovani G; Conti M; Spada A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3795-800. PubMed ID: 11502813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cyclic adenosine 3',5'-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsalpha gene.
    Peri A; Conforti B; Baglioni-Peri S; Luciani P; Cioppi F; Buci L; Corbetta S; Ballaré E; Serio M; Spada A
    J Clin Endocrinol Metab; 2001 May; 86(5):2111-7. PubMed ID: 11344215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
    Ezzat S; Zheng L; Asa SL
    Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone receptor expression and function in pituitary adenomas.
    Clausen LR; Kristiansen MT; Rasmussen LM; Billestrup N; Blaabjerg O; Ledet T; Jørgensen JO
    Clin Endocrinol (Oxf); 2004 May; 60(5):576-83. PubMed ID: 15104560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of GATA-2 in human pituitary adenomas.
    Umeoka K; Sanno N; Osamura RY; Teramoto A
    Mod Pathol; 2002 Jan; 15(1):11-7. PubMed ID: 11796836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.